logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2020 — A new combination for advanced melanoma progressing on anti-PD-L1

LEAP-004 study shows combination of lenvatinib, pembrolizumab is active in these patients.